NEW YORK (GenomeWeb News) — OpGen has received $23.6 million in Series A private-equity financing that it plans to use to “develop commercial instrumentation systems for the clinical microbiology marketplace.”
OpGen, a Madison, Wisc.-based company specializing in analyzing microbial DNA, also said it is looking for a new chief executive.
The cash came from three new venture capital investors, including CHL Medical Partners, Highland Capital Partners, and Versant Ventures. Existing investor Mason Wells also contributed in the round.
OpGen said it has added to its board of directors one investor each from Highland and Versant. Ron Lennox from CHL will become chairman of OpGen’s board, the company said. Lennox will be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.